Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. Show more
Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States
Market Cap
357.4M
52 Wk Range
$2.22 - $6.42
Previous Close
$3.44
Open
$3.45
Volume
3,390,220
Day Range
$3.44 - $3.64
Enterprise Value
161.8M
Cash
200.4M
Avg Qtr Burn
-44.61M
Insider Ownership
1.10%
Institutional Own.
85.55%
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nomlabofusp (CTI-1601) Details Friedreich’s Ataxia | BLA Submission |